16 September 2026 editorial review · Item
Stem-cell-derived islet clusters (Seraxis SR-02): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: SR-02 registry design and sponsor first-recipient reporting were reviewed. No quantitative peer-reviewed efficacy was located. Selection for severe hypoglycemia and the need for immunosuppression remain limits.
- Registry NCT07581197: NOT_YET_RECRUITING; updated 2026-05-12; enrollment 9 (ESTIMATED); primary completion 2028-11 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes (manufacturer).